Novartis drug “A” is used as an API and two polymers PLGA and Eudragit EPO are used in this work for co-formulation. Effect of drug to polymer ratio was studied by maintaining same thermodynamic conditions in a SCF based antisolvent system. With Eudragit EPO, it was observed that at higher drug loading, drug was precipitated into crystalline form with polymer coating. Maximum coating was observed at 70 to 30 drug to polymer ratio. But as polymer ratio increased, solid solution of drug and polymer was observed. With PLGA, one trial was conducted which showed good coating over the crystalline drug. Product was analyzed using SEM, Confocal Raman Microscopy, DSC, XRD and dissolution rate. On basis of these analysis, it was concluded that SCF process provides good approach for co-formulation and quality of co-formulation product can be tuned in this process.